Biofrontera Valuation
| BFRI Stock | USD 1.18 0.01 0.85% |
Today, the firm appears to be undervalued. Biofrontera shows a prevailing Real Value of $3.69 per share. The current price of the firm is $1.18. Our model approximates the value of Biofrontera from analyzing the firm fundamentals such as Return On Equity of -3.91, current valuation of 8.58 M, and Profit Margin of (0.36) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biofrontera's valuation include:
Price Book 1.8935 | Enterprise Value | Enterprise Value Ebitda (0.79) | Price Sales 0.2961 | Trailing PE 1.0172 |
Undervalued
Today
Please note that Biofrontera's price fluctuation is very risky at this time. Calculation of the real value of Biofrontera is based on 3 months time horizon. Increasing Biofrontera's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biofrontera is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biofrontera Stock. However, Biofrontera's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.18 | Real 3.69 | Target 11.5 | Hype 1.21 | Naive 1.22 |
The intrinsic value of Biofrontera's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Biofrontera's stock price.
Estimating the potential upside or downside of Biofrontera helps investors to forecast how Biofrontera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biofrontera more accurately as focusing exclusively on Biofrontera's fundamentals will not take into account other important factors: When choosing an evaluation method for Biofrontera, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Biofrontera Cash |
|
Biofrontera Valuation Trend
Biofrontera's real value analysis enables investors to forecast the earnings more efficiently. Using both Biofrontera's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Biofrontera Total Value Analysis
Biofrontera is currently projected to have valuation of 8.58 M with market capitalization of 10.47 M, debt of 5.4 M, and cash on hands of 31.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biofrontera fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.58 M | 10.47 M | 5.4 M | 31.91 M |
Biofrontera Investor Information
About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.89. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biofrontera had not issued any dividends in recent years. The entity had 1:20 split on the 5th of July 2023. Based on the key measurements obtained from Biofrontera's financial statements, Biofrontera is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Biofrontera Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biofrontera has an asset utilization ratio of 121.98 percent. This signifies that the Company is making $1.22 for each dollar of assets. An increasing asset utilization means that Biofrontera is more efficient with each dollar of assets it utilizes for everyday operations.Biofrontera Ownership Allocation
The market capitalization of Biofrontera is $10.47 Million. Biofrontera retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Biofrontera Profitability Analysis
The company reported the previous year's revenue of 34.07 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 16.66 M.About Biofrontera Valuation
An absolute valuation paradigm, as applied to Biofrontera Stock, attempts to find the value of Biofrontera based on its fundamental and basic technical indicators. By analyzing Biofrontera's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Biofrontera's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biofrontera. We calculate exposure to Biofrontera's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biofrontera's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 19.1 M | 14.3 M | |
| Pretax Profit Margin | (0.53) | (0.56) | |
| Operating Profit Margin | (0.77) | (0.80) | |
| Net Loss | (0.53) | (0.56) | |
| Gross Profit Margin | 0.56 | 0.54 |
Biofrontera Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.5 M |
Biofrontera Current Valuation Indicators
Valuation refers to the process of determining the present value of Biofrontera and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biofrontera we look at many different elements of the entity such as Biofrontera's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biofrontera, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biofrontera's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biofrontera's worth.Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |